Edition:
United States

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

31.92USD
19 Jun 2018
Change (% chg)

$-0.37 (-1.15%)
Prev Close
$32.29
Open
$31.99
Day's High
$32.10
Day's Low
$31.80
Volume
1,911,916
Avg. Vol
1,838,482
52-wk High
$37.20
52-wk Low
$24.54

Latest Key Developments (Source: Significant Developments)

Boston Scientific Announces Acquisition Of Securus Medical Group
Tuesday, 3 Apr 2018 07:00am EDT 

April 3 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES ACQUISITION OF SECURUS MEDICAL GROUP, INC..DEAL IS EXPECTED TO BE IMMATERIAL TO BOSTON SCIENTIFIC ADJUSTED AND GAAP EARNINGS PER SHARE​.FRONT.DEAL INCLUDES UP TO $10 MILLION IN CONTINGENT PAYMENTS BASED ON REGULATORY ACHIEVEMENTS AND COMMERCIAL MILESTONES.INFRARED ESOPHAGEAL TEMPERATURE MONITORING SYSTEM IS EXPECTED TO BE INTEGRATED INTO BOSTON SCIENTIFIC PORTFOLIO.INFRARED ESOPHAGEAL TEMPERATURE MONITORING SYSTEM IS EXPECTED TO BE COMMERCIALLY AVAILABLE IN U.S. IN FIRST HALF OF 2019​.  Full Article

Boston Scientific says co prevails in UK Edwards Lifesciences Litigation​
Wednesday, 28 Mar 2018 05:20am EDT 

March 28 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORP SAYS ‍BOSTON SCIENTIFIC PREVAILS IN U.K. EDWARDS LIFESCIENCES LITIGATION​.TO APPEAL U.S. PATENT OFFICE'S RECENT FINDING THAT CERTAIN CLAIMS OF CO'S U.S. PATENT 8,992,608 ASSERTED AGAINST EDWARDS ARE INVALID​.  Full Article

Boston Scientific Announces Agreement To Acquire NxThera
Wednesday, 21 Mar 2018 06:45am EDT 

March 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE NXTHERA.BOSTON SCIENTIFIC CORP - ‍TRANSACTION CONSISTS OF AN UPFRONT CASH PAYMENT OF $306 MILLION​.BOSTON SCIENTIFIC CORP - DEAL OF NXTHERA IS EXPECTED TO BE IMMATERIAL TO BOSTON SCIENTIFIC ADJUSTED EPS THROUGH 2020 AND ACCRETIVE THEREAFTER​.BOSTON SCIENTIFIC - ‍TRANSACTION ALSO CONSISTS OF UP TO ADDITIONAL $100 MILLION IN POTENTIAL COMMERCIAL MILESTONE PAYMENTS OVER NEXT FOUR YEARS​.BOSTON SCIENTIFIC CORP - DEAL IS EXPECTED TO BE DILUTIVE ON A GAAP BASIS, DUE TO AMORTIZATION AND TRANSACTION AND INTEGRATION COSTS​.BOSTON SCIENTIFIC - CO HAS EXISTING MINORITY INVESTMENT IN NXTHERA, EXPECTED TO RESULT IN UPFRONT PAYMENT OF ABOUT $240 MILLION & MILESTONE PAYMENTS OF UP TO $85 MILLION​.  Full Article

Late-Breaking Clinical Trial Data Further Demonstrate Safety And Effectiveness Of Rhythmia Mapping System
Tuesday, 20 Mar 2018 07:00am EDT 

March 20 (Reuters) - Boston Scientific Corp ::LATE-BREAKING CLINICAL TRIAL DATA FURTHER DEMONSTRATE SAFETY AND EFFECTIVENESS OF THE RHYTHMIA™ MAPPING SYSTEM.BOSTON SCIENTIFIC - DEPENDING ON ARRHYTHMIA TYPE, STUDY DATA SHOWED ACUTE SUCCESS RATE OF UP TO 95.7%.BOSTON SCIENTIFIC - WHEN COMPLETED, VALIDATION MAPPING IDENTIFIED NEED FOR ADDITIONAL ABLATIONS IN 73% OF PATIENTS.  Full Article

Boston Scientific Says Acquried EMcision
Monday, 5 Mar 2018 06:30am EST 

March 5 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES ACQUISITION OF EMCISION, LIMITED.BOSTON SCIENTIFIC CORP - ‍SPECIFIC TERMS OF TRANSACTION WERE NOT DISCLOSED.​.BOSTON SCIENTIFIC CORP - SPECIFIC TERMS OF TRANSACTION WERE NOT DISCLOSED..BOSTON SCIENTIFIC CORP - ACQUISITION OF EMCISION, LIMITED IS EXPECTED TO BE IMMATERIAL TO EARNINGS PER SHARE (EPS) IN 2018.BOSTON SCIENTIFIC - ACQUISITION OF EMCISION LIMITED IS EXPECTED TO BE ACCRETIVE TO EPS AFTER 2018.  Full Article

Boston Scientific Completes $1.0 Bln Offering Of Senior Notes
Monday, 26 Feb 2018 04:05pm EST 

Feb 26 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC COMPLETES $1.0 BILLION OFFERING OF SENIOR NOTES.  Full Article

Boston Scientific Prices $1 Billion Of Senior Notes
Thursday, 22 Feb 2018 05:30pm EST 

Feb 22 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PRICES $1.0 BILLION OF SENIOR NOTES.BOSTON SCIENTIFIC CORP - ‍PRICING OF PUBLIC OFFERING OF $1.0 BILLION 4.000% SENIOR NOTES DUE MARCH 1, 2028​.BOSTON SCIENTIFIC SAYS INTENDS TO USE NET PROCEEDS TO REDEEM 2.650% NOTES DUE OCTOBER 2018, TO REPAY SHORT TERM DEBT, AMONG OTHER.  Full Article

Boston Scientific Reports Q4 Adjusted Earnings Per Share $0.34
Thursday, 1 Feb 2018 06:30am EST 

Feb 1 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017.Q4 GAAP LOSS PER SHARE $0.45.Q4 SALES $2.408 BILLION VERSUS I/B/E/S VIEW $2.35 BILLION.Q4 EARNINGS PER SHARE VIEW $0.34 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 GAAP EARNINGS PER SHARE $0.93 TO $0.98.SEES Q1 2018 GAAP EARNINGS PER SHARE $0.19 TO $0.22.Q4 ADJUSTED EARNINGS PER SHARE $0.34.SEES FY 2018 REVENUE $9.65 BILLION TO $9.8 BILLION.SEES Q1 2018 SALES $2.32 BILLION TO $2.35 BILLION.QTRLY INTERVENTIONAL CARDIOLOGY SALES $636 MILLION VERSUS. $585 MILLION LAST YEAR.QTRLY CARDIAC RHYTHM MANAGEMENT SALES $488 MILLION VERSUS $473 MILLION LAST YEAR.Q4 LOSS PER SHARE OF $0.45 INCLUDES ESTIMATED ONE-TIME NET INCOME TAX CHARGE OF $861 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $1.35 TO $1.39.SEES Q1 2018 ADJUSTED EARNINGS PER SHARE $0.30 TO $0.32.FY2018 EARNINGS PER SHARE VIEW $1.38, REVENUE VIEW $9.61 BILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $0.31, REVENUE VIEW $2.32 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Boston Scientific Announces Investment And Acquisition Option Agreement With Millipede, Inc.
Wednesday, 24 Jan 2018 07:29am EST 

Jan 24 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES INVESTMENT AND ACQUISITION OPTION AGREEMENT WITH MILLIPEDE, INC..BOSTON SCIENTIFIC CORP - DEAL FOR $90 MILLION.BOSTON SCIENTIFIC - PURCHASED PORTION OF OUTSTANDING SHARES OF MILLIPEDE ALONG WITH NEWLY ISSUED SHARES OF CO.BOSTON SCIENTIFIC - HAS OPTION TO BUY REMAINING SHARES OF CO PRIOR TO COMPLETION OF FIRST IN HUMAN CLINICAL STUDY THAT MEETS SOME PARAMETERS.BOSTON SCIENTIFIC - ON COMPLETION OF CLINICAL STUDY, MILLIPEDE HAS OPTION TO COMPEL CO TO BUY ITS REMAINING SHARES.BOSTON SCIENTIFIC - COMPLETION OF DEAL WOULD RESULT IN ADDITIONAL $325 MILLION PAYMENT BY CO AT CLOSING.BOSTON SCIENTIFIC - COMPLETION OF DEAL WOULD ALSO RESULT IN ADDITIONAL $125 MILLION PAYABLE ON ACHIEVING COMMERCIAL MILESTONE.  Full Article

Boston Scientific Receives U.S. FDA Approval For Spectra Wavewriter Spinal Cord Stimulator System
Thursday, 11 Jan 2018 06:30am EST 

Jan 11 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR SPECTRA WAVEWRITER™ SPINAL CORD STIMULATOR SYSTEM.  Full Article

Medical device maker Stryker says not in talks to buy Boston Scientific

Medical device maker Stryker Corp is not in talks to buy rival Boston Scientific Corp , the company said in a regulatory filing https://bit.ly/2Jy6VQB on Wednesday, two days after a media report of a potential deal between the two surfaced.